| Announce Date | 12/09/2025 |
| EPS Normalized Actual | $-0.92 In Line |
| EPS GAAP Actual | $-0.92 In Line |
| Revenue Actual | $0.000463B |
| Revenue Surprise | Beat by $0.463M |
| Announce Date | 03/30/2026 (Pre-Market) |
| EPS Normalized Estimate | $-2.5 |
| EPS GAAP Estimate | $-2.5 |
| Revenue Estimate | $0.000874B |
| Fiscal Period Ending | EPS Estimate | Forward PE | Low | High | # of Analysts |
|---|---|---|---|---|---|
| Sep 2027 | 0.49269 | 35.26 | 0.49269 | 0.49269 | 0 |
| Sep 2026 | 0.35674 | 48.69 | 0.35674 | 0.35674 | 0 |
| Period | EPS | Beat / Miss | Revenue | YoY | Beat / Miss |
|---|---|---|---|---|---|
| FQ3 2025 (Sep 2025) | -1.19 | -1.19 | 0.000463B | 62.42% | 0.46M |
| FQ1 2019 (Mar 2019) | 0.29 | 0.29 | 0B | NAN% | 0M |
| FQ3 2019 (Sep 2019) | 0.29 | 0.29 | 0B | NAN% | 0M |
| FQ3 2024 (Sep 2024) | -3.45 | -3.45 | 0.000174B | 100% | 0.17M |
| FQ1 2025 (Mar 2025) | -1.34 | -0.84 | 0.000168B | 64.58% | -11.65M |
| FQ4 2023 (Dec 2023) | -0.0496 | -0.0496 | 5.95E-5B | 100% | 0.06M |
| FQ1 2024 (Mar 2024) | -0.0496 | -1.62605 | 5.95E-5B | 84.03% | -4M |
| FQ2 2023 (Jun 2023) | 0 | 0 | 0B | NAN% | 0M |
FQ4 Announce Date
03/30/2026 (Pre-Market)
Consensus EPS Estimates
-2.5
Consensus Revenue Estimates
0.000874B
| Fiscal Period Ending | EPS Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ1 2028 (Mar 2028) | -0.74 | -- | -0.74 | -0.74 | 1 |
| FQ4 2027 (Dec 2027) | 0 | -- | 0 | 0 | 0 |
| FQ2 2027 (Jun 2027) | 0 | -- | 0 | 0 | 0 |
| FQ1 2027 (Mar 2027) | 0 | -- | 0 | 0 | 0 |
| FQ4 2026 (Dec 2026) | -0.85 | -- | -0.85 | -0.85 | 1 |
| FQ2 2026 (Jun 2026) | -0.54 | -- | -0.54 | -0.54 | 1 |
| FQ1 2026 (Mar 2026) | -2.5 | 46.4 | -2.5 | -2.5 | 1 |
| Fiscal Period Ending | Revenue Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ1 2028 (Mar 2028) | 0B | -- | 0B | 0B | 1 |
| FQ4 2027 (Dec 2027) | 0B | -- | 0B | 0B | 1 |
| FQ2 2027 (Jun 2027) | 0B | -- | 0B | 0B | 1 |
| FQ1 2027 (Mar 2027) | 0B | -- | 0B | 0B | 1 |
| FQ4 2026 (Dec 2026) | 0B | -- | 0B | 0B | 1 |
| FQ2 2026 (Jun 2026) | 0B | -- | 0B | 0B | 1 |
| FQ1 2026 (Mar 2026) | 0B | 80.78 | 0B | 0B | 1 |
EPS # of Up Revisions
4
EPS # of Down Revisions
4
Revenue # of Up Revisions
6
Revenue # of Down Revisions
3
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
EPS # of Beats
2
EPS # of Misses
5
EPS # of in-lines
1
Revenue # of Beats
3
Revenue # of Misses
2
Revenue # of in-lines
3
| Earnings Date | EPS Estimate | EPS Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ3 2025 (Sep 2025) | -1.19 | -1.19 | 100% | |
| FQ1 2019 (Mar 2019) | 0.29 | 0.29 | 100% | |
| FQ3 2019 (Sep 2019) | 0.29 | 0.29 | 100% | |
| FQ3 2024 (Sep 2024) | -3.45 | -3.45 | 100% | |
| FQ1 2025 (Mar 2025) | -0.5 | -1.34 | -0.84 | 62.69% |
| FQ4 2023 (Dec 2023) | -0.0496 | -0.0496 | 100% | |
| FQ1 2024 (Mar 2024) | 1.57645 | -0.0496 | -1.62605 | 3278.33% |
| FQ2 2023 (Jun 2023) | 0 | 0 | NAN% |
| Earnings Date | Revenue Estimate | Revenue Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ3 2025 (Sep 2025) | $0B | $0B | $0.46M | 100% |
| FQ1 2019 (Mar 2019) | $0B | $0B | $0M | NAN% |
| FQ3 2019 (Sep 2019) | $0B | $0B | $0M | NAN% |
| FQ3 2024 (Sep 2024) | $0B | $0B | $0.17M | 100% |
| FQ1 2025 (Mar 2025) | $0.01B | $0B | $-11.65M | -6931.55% |
| FQ4 2023 (Dec 2023) | $0B | $0B | $0.06M | 100% |
| FQ1 2024 (Mar 2024) | $0B | $0B | $-4M | -6718.07% |
| FQ2 2023 (Jun 2023) | $0B | $0B | $0M | NAN% |